ALXN

Alexion Pharmaceuticals, Inc. Press Releases

$167.97
*  
4.60
2.82%
Get ALXN Alerts
*Delayed - data as of Jul. 22, 2014  -  Find a broker to begin trading ALXN now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Alexion Announces the Appointments of David R. Brennan, M. Michele Burns and Christopher J. Coughlin to Its Board of Directors
7/16/2014 8:00:00 AM - Business Wire

Alexion Pharmaceuticals to Report Second Quarter 2014 Results on Thursday, July 24, 2014
7/10/2014 10:00:00 AM - Business Wire

Raptor Announces CEO Succession Plan; Dr. Christopher Starr to Retire as CEO at Year-end 2014, Julie Anne Smith Named President and CEO-Designate
7/7/2014 4:01:00 PM - GlobeNewswire

Biotech Equities under the Scanner -- Research on Alexion Pharma, InterMune, Cytokinetics, and Biogen Idec
7/7/2014 5:55:00 AM - PR Newswire

Alexion and Cincinnati Children's Launch Rare Disease Innovation Fund
6/23/2014 6:30:00 AM - PR Newswire

Alexion and Cincinnati Children’s Launch Rare Disease Innovation Fund
6/23/2014 6:30:00 AM - Business Wire

FDA Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)
6/17/2014 6:39:00 AM - Business Wire

Biotech Equities under the Scanner -- Research on Halozyme Therapeutics, Medivation, Achillion Pharma, and Alexion Pharma
6/6/2014 8:10:00 AM - PR Newswire

Alexion to Present at Investor Conferences
6/3/2014 10:00:00 AM - Business Wire

New Data Presented at the ERA-EDTA Congress Demonstrate Efficacy of Soliris® (eculizumab) in Broad Range of Patients with atypical Hemolytic Uremic Syndrome (aHUS)
6/2/2014 7:15:00 AM - Business Wire

Alexion Initiates Voluntary Nationwide Recall of Certain Lots of Soliris® (eculizumab) Concentrated Solution for Intravenous Infusion Due to the Presence of Visible Particulate Matter in a Single Lot
6/2/2014 6:59:00 AM - Business Wire

Technical Updates on Biotech Stocks -- Research on Alexion Pharma, Acorda Therapeutics, Clovis Oncology, and Sangamo BioSciences
5/9/2014 12:30:00 PM - PR Newswire

New Data Detailing the Devastating Nature of Hypophosphatasia (HPP) and Treatment Effect of Asfotase Alfa in Infants, Young Children and Juveniles with HPP Presented at the Pediatric Academic Societies Meeting
5/5/2014 8:02:00 PM - Business Wire

FDA Approves Conversion of Soliris® (eculizumab) Accelerated Approval in aHUS to Regular Approval for the Treatment of Patients with aHUS
5/5/2014 6:30:00 AM - Business Wire

Alexion to Present at Investor Conferences
5/1/2014 10:00:00 AM - Business Wire